Regeneron quarterly profit nearly doubles on robust sales of COVID-19 therapy

(Reuters) – Regeneron Pharmaceuticals quarterly profit nearly doubled on Thursday, on strong sales of its COVID-19 antibody cocktail.

The drugmaker’s net profit rose to $2.23 billion, or $19.69 per share, in the fourth quarter ended Dec. 31, from $1.15 billion, or $10.24 per share, a year earlier.

(Reporting by Leroy Leo; Editing by Amy Caren Daniel)